ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,445
-1,30%
Bitcoin
70 194,16
-1,76%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aura Biosciences Inc (AURA)

  7. Aura Biosciences Inc (AURA) Actualités

AURA

Aura Biosciences (AURA)

Aura Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AURA
DateHeureSourceTitreSymboleSociété
09/05/202413h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AURAAura Biosciences Inc
09/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
09/05/202413h00GlobeNewswire Inc.Aura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
08/05/202413h00GlobeNewswire Inc.Aura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
27/03/202412h00Business WireAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
04/03/202423h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
07/12/202314h00Business WireAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
09/11/202322h05Business WireAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
07/11/202322h55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AURAAura Biosciences Inc
07/11/202304h02Business WireAura Biosciences Announces Pricing of Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202322h08Business WireAura Biosciences Announces Proposed Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202321h50Dow Jones NewsAura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-SarNASDAQ:AURAAura Biosciences Inc
06/11/202321h00Business WireAura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
31/10/202321h05Business WireAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023NASDAQ:AURAAura Biosciences Inc
24/10/202302h51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
02/10/202322h05Business WireAura Biosciences Strengthens and Expands Leadership Team with Key AppointmentsNASDAQ:AURAAura Biosciences Inc
09/08/202313h00Business WireAura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
09/06/202322h58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AURAAura Biosciences Inc
07/06/202323h47Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:AURAAura Biosciences Inc
07/06/202322h52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AURAAura Biosciences Inc
12/05/202313h00Business WireAura Biosciences to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:AURAAura Biosciences Inc
11/05/202322h28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AURAAura Biosciences Inc
11/05/202322h10Business WireAura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
25/04/202322h07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AURAAura Biosciences Inc
25/04/202322h06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AURAAura Biosciences Inc
15/03/202321h48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AURAAura Biosciences Inc
15/03/202321h38Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AURAAura Biosciences Inc
15/03/202321h10Business WireAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
16/02/202313h00Business WireAura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal AdministrationNASDAQ:AURAAura Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:AURA

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
EU
RNO
Renault
EU
CAP
Capgemini
NYSE
MRK
Merck
EU
AI
Air Liquide
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
EU
AF
Air FranceKLM
NYSE
MCD
McDonalds
EU
HO
Thales
EU
ML
Michelin
EU
ACA
Credit Agricole
NYSE
NKE
Nike
SPI
SP500
S&P 500
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés